PHOCUS: A phase 3 randomized, open-label study comparing the oncolytic immunotherapy Pexa-Vec followed by sorafenib (SOR) vs SOR in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy - Abou-Alfa, G K; Galle, P R; Chao, Y (2016)
(suppl; abstr TPS4146)